argenx (NASDAQ: ARGX) seals Forte deal for first-in-class autoimmune antibody
Rhea-AI Filing Summary
ARGENX SE (ARGX) completed the acquisition of Forte Biosciences, Inc. through a cash tender offer followed by a merger, making Forte a wholly owned subsidiary and removing its common stock from trading on the Nasdaq Capital Market. The deal brings FB102, a first-in-class anti-CD122 monoclonal antibody with clinical proof-of-concept in vitiligo and celiac disease, into the argenx immunology pipeline.
Through a subsidiary, argenx purchased all validly tendered Forte shares at $77.00 per share in cash. As of the tender expiration, 19,894,879 Forte shares had been validly tendered and not withdrawn, representing 87.13% of Forte’s issued and outstanding common stock together with shares already owned by argenx and its affiliates. All remaining Forte shares were converted into the right to receive the same cash amount per share in the subsequent merger. FB102 is being evaluated in Phase 2 celiac disease and Phase 1b alopecia areata studies, with data expected in the second half of 2026.
Positive
- Strategic pipeline expansion: Completion of the Forte acquisition adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, broadening ARGX’s immunology portfolio and targeting additional autoimmune indications.
Negative
- None.
Key Figures
Tender offer price per share: $77.00 per share
Shares tendered: 19,894,879 shares
Ownership percentage acquired via tender and existing holdings: 87.13%
+3 more
6 metrics
Tender offer price per share
$77.00 per share
Cash purchase price for each share of Forte common stock in tender offer and merger
Shares tendered
19,894,879 shares
Forte common shares validly tendered and not withdrawn as of offer expiration
Ownership percentage acquired via tender and existing holdings
87.13%
Portion of Forte’s issued and outstanding common stock represented by tendered shares plus shares already owned by argenx and affiliates
Tender offer expiration time
One minute after 11:59 p.m. Eastern Time on August 26, 2026
Expiration of the cash tender offer for Forte shares
FB102 Phase 2 celiac disease data timing
Second half of 2026
Expected timing for data readout from FB102 Phase 2 celiac disease study
FB102 Phase 1b alopecia areata data timing
Second half of 2026
Expected timing for data readout from FB102 Phase 1b alopecia areata trial
Key Terms
cash tender offer, clinical proof-of-concept, anti-CD122 antibody, Phase 2 celiac disease study, +2 more
6 terms
cash tender offer financial
"argenx completed the cash tender offer, through a subsidiary, for all the outstanding shares"
A cash tender offer is a public proposal in which an individual or group offers to buy a set number of a company's shares directly from shareholders for a specified cash price during a limited time. It matters to investors because it gives a clear, immediate chance to sell shares at a known price — like a store offering to buy back items at a posted rate — and can affect the stock’s market price, ownership control and liquidity.
clinical proof-of-concept medical
"FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo"
An early clinical proof-of-concept is initial human trial evidence showing a drug or medical treatment produces the intended biological effect or meaningful patient benefit. Think of it as the first successful test drive that proves the idea works in real-world conditions rather than just in the lab. For investors, it meaningfully lowers scientific risk and can boost a program’s valuation, partner interest, and likelihood of further funding or approval.
anti-CD122 antibody medical
"FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept"
A laboratory-made antibody that binds to CD122, the protein also known as the beta chain of certain immune-cell receptors, to change how immune cells respond. Think of it like a key designed to fit a specific lock on immune cells to dial immune activity up or down. Investors encounter this term because such antibodies are drug candidates whose clinical progress, safety results, and regulatory decisions can affect a biotech company’s value and future revenue prospects.
Phase 2 celiac disease study medical
"A Phase 2 celiac disease study has been initiated with data expected"
Phase 1b alopecia areata trial medical
"A Phase 1b alopecia areata trial is ongoing with data expected"
neonatal Fc receptor (FcRn) blocker medical
"argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker"
FAQ
What transaction did ARGENX (ARGX) announce in this Form 6-K?
ARGENX announced the completion of its acquisition of Forte Biosciences, Inc. It first conducted a cash tender offer and then merged a wholly owned subsidiary into Forte, making Forte a wholly owned subsidiary and delisting its common stock from the Nasdaq Capital Market.
What happens to Forte Biosciences’ stock after the ARGENX (ARGX) acquisition?
Following the merger, Forte Biosciences became a wholly owned subsidiary of ARGENX, and Forte’s common stock will no longer be listed or traded on the Nasdaq Capital Market. Remaining Forte shares were converted into the right to receive $77.00 per share in cash.
What is FB102 and why is it important to ARGENX (ARGX)?
FB102 is a proprietary, first-in-class anti-CD122 monoclonal antibody with clinical proof-of-concept in vitiligo and celiac disease. It has potentially broad autoimmune applications and complements ARGENX’s existing antibody-based programs by targeting pathogenic T-cell and NK-cell activity.
What are the key clinical timelines for FB102 after the ARGENX (ARGX) acquisition?
FB102 is in a Phase 2 celiac disease study with data expected in the second half of 2026. A Phase 1b alopecia areata trial is also ongoing, with data expected in the second half of 2026, and vitiligo data were reported in July 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
